Biotron Limited
A.B.N. 60 086 399 144

NEW BIOTRON CEO COMMENCES

Highlights:

- Biotron CEO and Executive Director Glenn Gilbert has commenced, bringing forward his start date from January 2027.
- Mr Gilbert brings extensive experience across clinical and regulatory development, manufacturing, commercialisation, business development and capital raising.
- His immediate priorities will include reviewing Biotron's development portfolio, defining the next-stage strategy for SedRx, and evaluating the optimal development and partnering pathways for the Company's assets.

9 November 2026 **Biotron Limited** (ASX: **BIT**) is pleased to announce that Mr Glenn Gilbert has commenced as Chief Executive Officer and Executive Director, effective immediately, bringing forward his previously announced commencement date of 18 January 2027.

Mr Gilbert's earlier commencement enables the Company to immediately progress a strategic and operational review of its development portfolio and establish clear priorities for the next phase of Biotron's growth. It will also facilitate engagement with Biotron's key stakeholders, development partners and the broader investment community.

A key focus will be SedRx, Biotron's next-generation alfaxalone-based general anaesthetic, including its regulatory, clinical, manufacturing and partnering pathway. The review will also consider the development and commercialisation strategy for the Company's broader portfolio, including BIT-HBV001 and additional potential neurology opportunities.

Mr Gilbert's experience spans quality, regulatory and clinical development, commercialisation, manufacturing, international business development and capital raising. His appointment comes at a critical stage for Biotron as the Company seeks to sharpen development priorities, optimise capital allocation and position its assets for future partnering and commercialisation.

Chairman, Mr Paul Kasian said, "Glenn's earlier commencement allows us to accelerate an important strategic review of Biotron's portfolio and establish clear priorities for the next stage of the Company's development. I am enthusiastic about working with Glenn to realise the value of Biotron's intellectual property and build a disciplined and commercially focussed company."

CEO & Executive Director, Mr Glenn Gilbert added, "Biotron has a number of potentially valuable assets, with SedRx representing an important near-term strategic opportunity. My immediate focus will be to work with the Board and our advisers to establish clear

development priorities, define the regulatory and commercial pathways for the key programs and ensure that capital is directed toward activities capable of delivering meaningful shareholder value."

This announcement has been approved by the Board of Directors of Biotron Limited

FOR FURTHER INFORMATION

Marcelo Mora
Company Secretary
Biotron Limited
T: +61 2 9300 3344
E: mmora@miscorp.com.au
W: www.biotron.com.au

Rudi Michelson
Monsoon Communications
T: +61 411 402 737
E: rudim@monsoon.com.au

pjn13043

About Biotron Limited

Biotron Limited (ASX: BIT) is an Australian biotechnology company focused on developing and commercialising novel therapeutics across anaesthesia, neuroscience, and antiviral medicine. Its lead asset, SedRx, is a next-generation alfaxalone-based general anaesthetic supported by existing human clinical data and being advanced through regulatory planning for pivotal development, alongside evaluation of potential additional neuroscientific indications. Biotron continues to develop BIT-HBV001, a novel antiviral candidate targeting Hepatitis B and Hepatitis Delta viruses, while pursuing partnering and commercialisation opportunities across its portfolio.

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**BIOTRON LIMITED**
ABN	**60 086 399 144**

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Glenn Gilbert
Date of appointment	9 November 2026

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	**Number & class of Securities**
Nil	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.